Wang Jian, a 1996 graduate from the College of Veterinary Medicine at Nanjing Agricultural University with a major in Veterinary Science, and a 2015 graduate from Nankai University with an MBA, is currently the Chairman of Tianjin Speerise Challenge Biotechnology co.,ltd. and the Dean of the Challenge Animal Health Research Institute.
Since joining the workforce, Wang Jian has been actively engaged in research and promotion in the field of veterinary pharmacology, with a particular focus on poultry and swine diseases. Over the years, through extensive market research and in response to market demands, he has led his R&D team to develop a variety of new veterinary drugs and generic drugs, holding several invention patents for drug preparation. He has presided over or participated in the research and approval of more than ten new veterinary drugs, including ceftiofur hydrochloride injection, long-acting doxycycline injection, refined egg yolk antibody for duck viral hepatitis, rifaximin mammary injection, diclofenac sodium injection, compound acetaminophen, diclofenac sodium injection, 20% enrofloxacin injection, lentinan polysaccharide and lentinan polysaccharide soluble powder, refined egg yolk antibody for goose parvovirus, altrenogest and altrenogest oral solution, Gamithromycin and gamithromycin injection, tyramycin and tyramycin injection, etc. In recent years, he has led the team to actively carry out research on new vaccines and cell therapy products for animals, and has made gratifying progress.Most of these products have received strong market responses and widespread recognition.
